Search results
Actinium Announces Multiple Abstracts Highlighting its Antibody Radiation Conjugates Iomab-B and...
WJTV Jackson· 4 hours agoIomab-B and Actimab-A are the only targeted radiotherapies in development for patients with relapsed/refractory acute myeloid leukemia
Venetoclax Combo Safe, Effective in AML Patients Age 80 and Up, Real-World Data Show
MedPage Today· 4 days agoVenetoclax (Venclexta) combined with a hypomethylating agent (HMA) -- the standard of care for older...
Small Business - Austin Daily Herald | Austin Daily Herald
Austin Daily Herald· 4 hours agoAML is a cancer of the blood and bone marrow and is the most common type of acute leukemia in adults. SENTI-202, a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor ...
Obituary - Steven Michael Kakuska
Fontana Herald News· 3 days agoSteven Michael Kakuska’s battle with acute myeloid leukemia ended on Saturday, March 27, when he passed away at Kaiser Hospital in Fontana ...
Older adults with aggressive blood cancer are responsive to treatment and show prolonged survival:...
Medical Xpress· 4 days agoStandard of care treatment for acute myeloid leukemia (AML) is safe and effective for adults over...
Earnings call: Kura Oncology reports on ziftomenib's progress By Investing.com
Investing.com· 7 days agoZiftomenib has received Breakthrough Therapy designation from the FDA for the treatment of...
Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update
FOX 23 News Albany· 5 hours agoMoleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses ...
Researchers discover new target for potential leukemia therapy
Medical Xpress· 5 days agoThe study provides both mechanistic and preclinical evidence supporting the rapid initiation of...
2 Incredible Growth Stocks to Buy Hand Over Fist
Motley Fool via Yahoo Finance· 5 days agoThis novel oral treatment for leukemia has the potential to surpass $1 billion in sales if it secures regulatory nods in both the front- and later-line...
TC BioPharm Announces Exercise of Warrants for £3.1 Million Gross Proceeds
Morningstar· 7 days agoTC BioPharm (Holdings) plc ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today ...